daratumumab
janssen
['multiple myeloma', 'maia', 'daratumumab', 'mmsm']
a subgroup analysis of the phase 3 maia trial showed rapid, deep, and durable responses with daratumumab plus lenalidomide and dexamethasone vs standard therapy for newly diagnosed multiple myeloma across patient subgroups. #mmsm #asco22 | 
Home of the journal ONCOLOGY®, CancerNetwork® offers different perspectives on oncology/hematology through review articles, news, podcasts, blogs, and more.